Traders sold shares of Eli Lilly and Co. (NYSE:LLY) on strength during trading on Monday. $29.00 million flowed into the stock on the tick-up and $71.71 million flowed out of the stock on the tick-down, for a money net flow of $42.71 million out of the stock. Of all equities tracked, Eli Lilly and had the 0th highest net out-flow for the day. Eli Lilly and traded up $0.04 for the day and closed at $80.26

Several brokerages have issued reports on LLY. Argus boosted their target price on Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, August 2nd. Morgan Stanley restated a “hold” rating and set a $88.00 target price on shares of Eli Lilly and in a research report on Saturday, June 4th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $92.00 target price for the company in a research report on Friday, August 5th. Leerink Swann restated a “buy” rating on shares of Eli Lilly and in a research report on Sunday, June 26th. Finally, Credit Suisse Group AG restated an “overweight” rating on shares of Eli Lilly and in a research report on Tuesday, April 26th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $96.35.

The stock’s 50-day moving average is $80.48 and its 200-day moving average is $75.91. The stock has a market cap of $84.81 billion and a PE ratio of 34.562.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.86. During the same period in the previous year, the business posted $0.90 EPS. The company had revenue of $5.40 billion for the quarter, compared to analysts’ expectations of $5.14 billion. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. On average, analysts predict that Eli Lilly and Co. will post $3.59 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be given a dividend of $0.51 per share. The ex-dividend date is Thursday, August 11th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.54%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 240,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $82.87, for a total value of $19,888,800.00. Following the completion of the transaction, the insider now owns 126,020,570 shares of the company’s stock, valued at approximately $10,443,324,635.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Melissa S. Barnes sold 992 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $73.77, for a total transaction of $73,179.84. Following the completion of the transaction, the senior vice president now directly owns 10,710 shares of the company’s stock, valued at approximately $790,076.70. The disclosure for this sale can be found here.

Other institutional investors have modified their holdings of the company. TCI Wealth Advisors Inc. boosted its position in shares of Eli Lilly and by 0.5% in the fourth quarter. TCI Wealth Advisors Inc. now owns 14,349 shares of the company’s stock valued at $1,209,000 after buying an additional 76 shares in the last quarter. Budros Ruhlin & Roe Inc. boosted its stake in Eli Lilly and by 0.4% in the fourth quarter. Budros Ruhlin & Roe Inc. now owns 27,156 shares of the company’s stock valued at $2,288,000 after buying an additional 121 shares during the period. Dorsey & Whitney Trust CO LLC boosted its stake in Eli Lilly and by 1.2% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 20,579 shares of the company’s stock valued at $1,734,000 after buying an additional 239 shares during the period. Homrich & Berg boosted its stake in Eli Lilly and by 1.9% in the fourth quarter. Homrich & Berg now owns 16,855 shares of the company’s stock valued at $1,420,000 after buying an additional 317 shares during the period. Finally, Palladium Partners LLC boosted its stake in Eli Lilly and by 0.4% in the fourth quarter. Palladium Partners LLC now owns 152,214 shares of the company’s stock valued at $12,826,000 after buying an additional 531 shares during the period.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.